GM1 gangliosidosis market projected to reach $0.95B by 2030 at 10.8% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The GM1 Gangliosidosis Market Expected To Change From 2026 To 2030?

The gm1 gangliosidosis market has experienced substantial expansion in recent years. It is projected to expand from $0.57 billion in 2025 to $0.63 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.1%. This historical growth can be attributed to key factors such as rare disease research initiatives, the identification of enzyme deficiencies, advancements in genetic diagnostics, hospital-based pediatric care, and initial clinical studies.

The gm1 gangliosidosis market is projected to experience substantial growth over the coming years. It is anticipated to expand to $0.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. This expansion during the forecast period can be attributed to the advancement of the gene therapy pipeline, orphan drug incentives, more effective diagnostic screening, heightened patient advocacy, and increased biotechnology funding. Significant trends for this period include an intensified focus on developing drugs for rare diseases, greater research into gene therapy, the expanding application of enzyme replacement therapies, the broadening of newborn genetic screening, and a rise in clinical trial activity.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

Which Important Drivers Are Guiding The GM1 Gangliosidosis Market Growth?

The rising acceptance of gene therapy is anticipated to stimulate the expansion of the GM1 gangliosidosis market. Gene therapy represents a medical intervention designed to modify or replace genes within an individual’s cells to either treat existing conditions or prevent their onset. The increasing adoption of this therapy is driven by advancements in genetic research, enhanced treatment outcomes for ailments previously deemed untreatable, and growing regulatory encouragement for innovative therapeutic approaches. For GM1 gangliosidosis, gene therapy functions by introducing a working version of the defective GLB1 gene into patient cells, aiming to reactivate β-galactosidase enzyme activity and thereby lessen the harmful buildup of substrates. For example, in January 2024, data from the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, indicated that the number of gene therapies in Phase III increased by 10% in Q4 2023 compared to the preceding quarter, signifying the first such rise since Q3 2022. Therefore, the expanding use of gene therapy is a key factor propelling the growth of the GM1 gangliosidosis market.

How Is The GM1 Gangliosidosis Market Categorized Across Its Segment Groups?

The gm1 gangliosidosis market covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy

3) By End-User: Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset

What Trends Are Influencing The Evolution Of The GM1 Gangliosidosis Market?

Leading companies active in the GM1 gangliosidosis market are concentrating on strategic alliances to secure their market position. These strategic partnerships are crucial for progressing gene therapy development by combining shared expertise, resources, and technologies to accelerate research, clinical trials, and eventual commercialization. For example, in October 2024, GEMMA Biotherapeutics Inc., a US-based biotechnology firm, joined forces with the Oswaldo Cruz Foundation (Fiocruz), a health research institution from Brazil, to develop gene therapies for rare diseases, including GM1 gangliosidosis. The arrangement includes up to $100 million in funding from Fiocruz for clinical research and manufacturing, intended to make these advanced therapies accessible through Brazil’s public healthcare system. This cooperative effort underscores technology transfer and aims to widen access to treatments that were previously limited to wealthier populations.

Which Firms Are Influencing Competition In The GM1 Gangliosidosis Market?

Major companies operating in the gm1 gangliosidosis market are Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics Inc

Get The Full GM1 Gangliosidosis Market Report:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

Which Region Has The Greatest Market Share In The GM1 Gangliosidosis Market?

North America was the largest region in the GM1 gangliosidosis market in 2025. The regions covered in the gm1 gangliosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized GM1 Gangliosidosis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

Browse Through More Reports Similar to the Global GM1 Gangliosidosis Market 2026, By The Business Research Company

Glycol Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycol-global-market-report

Alpha Mannosidosis Market 2026

https://www.thebusinessresearchcompany.com/report/alpha-mannosidosis-global-market

Paraganglioma Market Report 2026

https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795